Crossmark

Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles

Crossref DOI link: https://doi.org/10.1186/s12885-018-4393-7

Published Online: 2018-04-23

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wu, Shu-ta

Fowler, Anthony J.

Garmon, Corey B.

Fessler, Adam B.

Ogle, Joshua D.

Grover, Kajal R.

Allen, Bailey C.

Williams, Chandra D.

Zhou, Ru

Yazdanifar, Mahboubeh

Ogle, Craig A.

Mukherjee, Pinku http://orcid.org/0000-0002-6782-3576
Funding

Funding for this research was provided by:

CPCP Levine UNCC Pancreatic Cancer Pilot Project

UNC Charlotte Faculty Research Grant

UNC Charlotte, The Williams States Lee College of Engineering, Center for Biomedical Engineering and Sciences IVIS Imaging System Award
License Information

Text and Data Mining valid from 2018-04-23
More Information

Article History

Received: 28 September 2017

Accepted: 17 April 2018

First Online: 23 April 2018

Ethics approval and consent to participate

: All procedures were approved and conducted in accordance to the Institutional Animal Care and Use Committee of UNC Charlotte.

: The authors declare the following competing interests:PM is co-founder and Chief Scientific Officer of OncoTAb, Inc.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.